CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
ConditionMZL
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHenan Cancer Hospital
About this trial
This is a multicenter, real-world study on first-line CD20 monoclonal antibody-based regimens for treatment-naive marginal zone B-cell lymphoma based on risk stratification. The primary objective is to evaluate the efficacy and safety of the "BR", "R2", and "OR2" treatment regimens in treatment-naive MZL patients receiving first-line CD20 monoclonal antibody-based therapy stratified by risk.
Eligibility criteria
Qualifiers
Histologically confirmed marginal zone B-cell lymphoma (MZL) in accordance with the 2016 WHO classification;
Age ≥ 18 years, with no gender restriction;
Gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), HP-positive or HP-negative, with progression/relapse after local therapy (including surgery, radiotherapy, and anti-Helicobacter pylori treatment);
ECOG performance status 0, 1, or 2 (Appendix 4);
Disqualifiers
Histological transformation to high-grade lymphoma.
Known central nervous system (CNS) involvement by lymphoma or evidence of CNS disease.
Prior systemic therapy, including immunotherapy, chemotherapy, or targeted therapy.
Prior autologous stem cell transplantation, or allogeneic tissue / solid organ transplantation.
Trial design
Treatments tested in this trial
- R2/BR/OR2
Treatment groups
131 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov